n/a
Dr. Zelalem Temesgen MD is an infectious diseases physician and a Professor of Medicine, Mayo Clinic College of Medicine and Science. He serves as director of the Mayo Clinic HIV program and the Mayo Clinic Center for Tuberculosis as well as being actively involved in education and research. His educational activities have been acknowledged with a “Recognition for Teaching” award, “Best Teacher of the Year” award, an “Innovation in Education” award, and the “Mayo Clinic Distinguished Educator” award, the highest award for education given at Mayo Clinic.
Dr. Temesgen has served as the principal investigator for over 40 clinical trials, including as site principal investigator (PI) for several NIH-sponsored trials in HIV, influenza, COVID-19, and c. difficile infections. Additional research-related experience includes several years’ service as a member of the Mayo Clinic Institutional Review Board (IRB) and membership in as well as chairing Data and Safety Monitoring Boards. His bibliography currently lists over 180 peer-reviewed papers, 21 book chapters, 4 editorials, 2 indexed letters, 3 books, and numerous abstracts presented at professional meetings. Dr. Temesgen is the editor-in-chief of the Clinical Journal of Tuberculosis and other Mycobacterial Diseases and editor-in-chief of 3 books: Mayo Clinic Infectious Diseases Board Review Book; Fundamentals of Global HIV Medicine; and General Approach to Infectious Diseases.
Dr. Temesgen serves as a member of: US DHHS Advisory Council for the Elimination of Tuberculosis and the World Health Organization Taskforce on Digital Health for Tuberculosis. Past services include: Chair, American Academy of HIV Medicine; member, US Presidential Advisory Council on HIV/AIDS; member, Lancet Commission on Tuberculosis; member, DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents; member, Scientific Advisory Board for the US President’s Emergency Plan for AIDS Relief (PEPFAR); and member the National Board of Medical Examiners USMLE Microbiology & Immunology Test Material Development Committee.
Disclosure information not submitted.
Tuesday, April 19, 2022
1:00 PM – 2:00 PM US CST